Immunotherapy plus chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of esophageal cancer called squamous cell carcinoma, and it must be in the chest area, not spread to other organs.
- You must be healthy enough for surgery (no major heart problems or other serious conditions).
- You have not had any prior treatment for this cancer, such as chemotherapy, radiation, or surgery.
- Your blood counts and liver, kidney, and clotting function must be within acceptable ranges.
- If you could become pregnant, you must take birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.